Cardiogen for Health & Longevity

Evidence Review created on 09/01/2026 using AI4L / Opus 5

Also known as: Ala-Glu-Asp-Arg, AEDR, H-Ala-Glu-Asp-Arg-OH, Alanyl-Glutamyl-Aspartyl-Arginine

Motivation

Cardiogen is a laboratory-made peptide: a chain of just four amino acid building blocks, assembled in Russia as one of a family of compounds each aimed at a single organ. Cardiogen’s assigned organ is the heart. The idea behind it is that very short peptides normally present in tissue carry instructions to the cells around them, and that supplying the heart’s own signal might restore how an ageing heart maintains and repairs itself.

The family grew out of Soviet military medical research in the 1970s on extracts taken from animal organs; synthetic four-amino-acid versions followed, and they now sell worldwide as freeze-dried powder in vials labelled for laboratory use only. Almost everything published on Cardiogen itself comes from the single research institute that created it, and none of that work involved people.

This review sets out what is known about Cardiogen: the biology proposed for it, the studies behind each claimed effect and each claimed harm, how far the protocols in circulation rest on that evidence, and which markers a person tracking cardiovascular ageing could follow.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Cardiogen

Consolidates the scattered preclinical record, from sequence and tissue-culture findings to the sarcoma experiment and the patent-only cardioprotection claims, and states plainly that no human study and no regulatory approval exist.

Examine

No Examine.com article exists for Cardiogen. Examine covers dietary supplements and food-derived compounds; Cardiogen is neither, being sold only as a research chemical, which is why the site does not index it.

ConsumerLab

No ConsumerLab article exists for Cardiogen. ConsumerLab tests consumer supplement products; Cardiogen is not sold as a supplement in the United States, so it falls outside the testing programme.

Systematic Reviews

Systematic reviews and meta-analyses that bear on Cardiogen and the short peptide class it belongs to.

Peptide Regulation of Gene Expression: A Systematic Review - Khavinson et al., 2021

Maps how short peptides, Cardiogen among them, bind DNA and histone proteins to alter transcription. Authored by the group that created and commercialises the compound.

PubMed indexes no other systematic review or meta-analysis naming Cardiogen, its sequence, or the Khavinson short peptide bioregulators, so one paper is listed rather than five.

The trade-off here is between a claimed cardiac maintenance effect and the hazards of an unapproved, unregulated injectable. Only the first side is represented, and only indirectly, through gene-regulation evidence; no systematic review or meta-analysis addresses the safety of research-use-only peptide products, so the risk side is unrepresented in this section.

Mechanism of Action

Cardiogen is the tetrapeptide alanine-glutamate-aspartate-arginine, written AEDR (the one-letter code for those amino acids), with a molecular mass near 489 daltons.

Its originators propose that peptides this small enter the cell nucleus, dock onto histone tails and short stretches of promoter DNA, and shift transcription in the tissue the sequence matches. Fluorescence work confirms that AEDR binds isolated histone proteins in a site-specific way (Fedoreyeva et al., 2013). Downstream, heart explants exposed to Cardiogen show reduced p53 (a protein that pushes damaged cells into self-destruction), and cultured fibroblasts raise actin, tubulin, vimentin, lamin A and lamin C two- to fivefold. Entry is proposed through LAT1 and LAT2 (transporters that carry large amino acids into cells) and PEPT1 (a peptide transporter in the gut wall), but the evidence is computer docking, not measured uptake.

A competing reading is that none of this is signalling. Active concentrations in tissue culture are a million-millionth molar while circulating protocols use milligrams, no receptor has been identified, and peptidases (enzymes that chop peptides apart) are everywhere, so the shifts may reflect amino acid supply or assay artefact.

Pharmacological properties are largely unmeasured. No human half-life exists, although peptides of this length are hydrolysed within minutes; selectivity for heart tissue is asserted rather than shown by binding; tissue distribution has never been imaged; and clearance is peptidase breakdown to free amino acids rather than cytochrome P450 metabolism (the liver enzyme system that clears most medicines).

Historical Context & Evolution

The original use was military and clinical, not longevity. From the 1970s, researchers at the Kirov Military Medical Academy in Leningrad extracted low-molecular-weight polypeptide fractions from animal thymus and pineal glands and gave them to patients with radiation injury and immune suppression. Those extracts, thymalin and epithalamin, were the parent preparations.

Interest turned toward health optimisation when the same group reported that long-term dosing extended mean lifespan in rodents by 20-40%, slowed several ageing biomarkers, and suppressed both spontaneous and chemically induced tumours, alongside six to twelve years of clinical application (Anisimov & Khavinson, 2010). The Saint Petersburg Institute of Bioregulation and Gerontology was founded in 1992 to carry that programme forward, and synthetic two-, three- and four-amino-acid analogues were built from the amino acid composition of the natural extracts. Cardiogen is the heart-directed member of that synthetic series. Every one of these findings comes from the institute holding the patents and the commercial interest, and the rodent lifespan results have not been reproduced by an unaffiliated laboratory.

Opinion has since moved in both directions rather than settling. Independent groups began characterising the family from 2025, finding the structural chemistry thin (Araj et al., 2025). Regulators moved several longevity peptides into a restricted compounding category in 2023, then an advisory committee narrowly recommended six of them for compounding in 2026, a change petitioned for by pharmacies and clinics that bill for these preparations.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High. That grade requires a human clinical endpoint or a validated clinical surrogate, replicated across trials, and Cardiogen has never been given to human participants in a published study.

Medium 🟩 🟩

Nothing reaches Medium either. That grade requires the same class of human outcome in one trial or in consistent observational data; no trial and no cohort has measured anything after Cardiogen exposure.

Low 🟩

Speculative 🟨

Proliferative Activity in Aged Heart Tissue

Heart explants from young and aged rats, kept in organotypic culture (living tissue fragments), showed increased proliferation with Cardiogen (Chalisova et al., 2009). The basis is ex vivo only; no human counterpart exists.

Suppression of Apoptotic Signalling in Heart Tissue

The same explants showed reduced p53 staining, read by the authors as apoptosis (programmed cell death) being held back (Chalisova et al., 2009). This is a stain intensity, not a measured survival outcome.

Structural Protein Output in Fibroblasts

Cultured mouse embryonic fibroblasts raised actin, tubulin and vimentin two- to fivefold and lamins A and C two- to threefold (Khavinson et al., 2012). Cell culture only, in non-cardiac cells.

Tissue-Selective Action Across Organs

Cardiogen stimulated heart explants while sibling peptides stimulated their own target organs, which the authors read as tissue specificity (Zakutskii et al., 2006). No receptor or uptake measurement supports the interpretation.

Damping of Cell-Ageing Inflammatory Signalling

The originating group lists Cardiogen’s sequence among peptides said to modulate inflammaging (the low-grade inflammation of ageing) in heart and vessel cells (Khavinson et al., 2022). This is a review proposal, not an experiment.

Tumour Growth Restraint in Aged Rats

In aged rats carrying transplanted M-1 sarcoma, Cardiogen slowed growth dose-dependently by causing tumour tissue to die from bleeding and by raising tumour cell apoptosis (Levdik & Knyazkin, 2009). One rodent model.

Post-Infarction Survival Benefit (Patent-Only Claim)

Rat coronary-ligation experiments reporting threefold lower mortality and smaller areas of dead tissue appear in patent filings, not in peer-reviewed literature. No indexed publication reproduces them, so the basis is unverified proprietary data.

Benefit-Modifying Factors

Amino acid transporter variants: Uptake is proposed through LAT1 and PEPT1. Variants exist in both genes, including a rare F28Y variant of SLC15A1 (the PEPT1 gene) that cuts transport of peptide-like drugs (Anderle et al., 2006), so carriers would absorb differently if the mechanism holds.
Transporter genotype and ageing trajectory: Variation in SLC7A5 and related amino acid transporter genes tracks with physical decline and survival after 90 (Crocco et al., 2018). The same genotypes plausibly set how much a transporter-dependent peptide could deliver.
Baseline inflammatory markers: The proposed target is cell-ageing inflammation. Someone entering with high-sensitivity C-reactive protein (a general marker of inflammation) already below 0.5 mg/L has almost no margin for a measurable effect, whereas an elevated baseline leaves room.
Baseline cardiac reserve: Effects were largest in explants from 24-month rats, whose proliferative capacity had fallen. Preserved reserve, indicated by normal wall motion and a normal natriuretic peptide, offers less to restore than an already remodelled heart.
Sex: Unknown. The rodent and explant work used male animals or did not report sex, and no human data exist, so any sex difference in absorption, distribution or response is entirely uncharacterised for this compound.
Pre-existing cardiac disease: Claims concentrate on damaged and ageing heart muscle. Someone with a prior heart attack, treated high blood pressure or a stiff, poorly filling heart is the population the mechanism addresses; a structurally normal heart is not.
Age: The only comparative data contrast 3-month with 24-month rats, roughly young adult against advanced old age. Nothing addresses the 50-75 band, and the reserve that older adults have lost may also be the reserve required to respond.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High. That grade requires documented adverse events or a validated clinical surrogate replicated across more than one trial, and Cardiogen has never been given to human participants in a published study.

Medium 🟥 🟥

Nothing reaches Medium either. That grade requires the same class of human outcome in a single trial or in consistent observational data, and no human trial and no observational cohort reports outcomes after Cardiogen exposure.

Low 🟥

Immune Reactions to Synthesis By-Products

Peptides built by solid-phase synthesis carry truncated and modified by-products that can present new immune targets and provoke unwanted immune responses (De Groot et al., 2023). The evidence comes from regulated generic peptide medicines, so it reaches Cardiogen only by extension. Research-grade material undergoes no comparable assessment.

Magnitude: Risk rises with impurity load and with repeated dosing, and is highest for sequences carrying strong immune-binding motifs; the literature reports no outcome figure for Cardiogen or any bioregulator peptide.

Endotoxin Exposure from Unregulated Vials

Vials bought from unlicensed online sellers carried bacterial endotoxin, the fever-inducing fragment of bacterial cell wall, in every sample tested (Ashraf et al., 2024). That work sampled a different peptide moving through the same supply channel as Cardiogen. Injected endotoxin produces fever, shaking chills and inflammatory flares.

Magnitude: Endotoxin was present in 3 of 3 delivered vials at 2.16 to 8.95 endotoxin units per milligram.

Dose and Identity Error from Mislabelled Product

The same market surveillance measured purity far below the printed claim and peptide content well above the stated amount (Ashraf et al., 2024). A milligram figure on a protocol therefore does not describe what is administered. Cardiogen is sold through that identical channel, without prescription and without pharmacy oversight.

Magnitude: Purity ran 7.7% to 14.4% against a 99% label claim, and content exceeded the label by 28.6% to 38.7%, in every vial delivered.

Injection-Site Infection and Local Reactions

Self-administered injections of unregulated, non-pharmacy products have produced skin and soft-tissue infections, including a Mycobacterium fortuitum abscess after a clinic-supplied hormone injection (Neill et al., 2017). Cardiogen is reconstituted and injected outside any pharmacy setting. Local pain, redness and hardening are the milder end of the same route.

Magnitude: Not quantified in available studies. Only case reports describe infection after self-injection of unregulated products, and no cohort has counted injection-site events for any bioregulator peptide.

Speculative 🟨

Weakening of a Tumour-Suppressor Pathway

Reduced p53 in cardiac explants is the claimed benefit (Chalisova et al., 2009); the same shift removes a brake on damaged cells. No study has looked for tumour promotion. The concern is mechanistic.

Action on Tumour Blood Supply

In aged rats with transplanted sarcoma, Cardiogen altered tumour blood vessels enough to kill tumour tissue by bleeding (Levdik & Knyazkin, 2009). A compound that remodels tumour vessels may act on vessels elsewhere; untested.

Pro-Fibrotic Drift in Cardiac Fibroblasts

Cardiogen raises structural protein output in fibroblasts several-fold (Khavinson et al., 2012). Fibroblast activation also drives cardiac fibrosis, the replacement of muscle by stiff scar. No study separates repair from scarring.

Off-Target Binding to Histones and DNA

AEDR binds several histone types and methylated DNA without sequence exclusivity (Fedoreyeva et al., 2013). Gene regulation reaching beyond heart tissue is therefore plausible. No expression profiling outside cardiac and fibroblast models has been published.

Uncharacterised Reproductive and Genotoxic Effects

No reproductive, developmental or genotoxicity (DNA damage) testing of Cardiogen has been published, and suppliers cite that absence when listing pregnancy as a contraindication. The basis is missing data rather than observed harm.

Risk-Modifying Factors

Transporter genotype: Variants in SLC15A1 (which encodes the gut peptide transporter) and SLC7A5 (which encodes a large amino acid transporter) alter how much peptide-like material enters cells, so identical doses could give different exposures (Anderle et al., 2006).
Baseline biomarkers: An already elevated high-sensitivity troponin (a marker of heart-muscle injury) or natriuretic peptide signals ongoing myocardial stress, which makes any new inflammatory insult from a contaminated injection harder to distinguish and more consequential.
Sex: No sex-stratified data exist for this compound. Women carry higher rates of drug hypersensitivity generally, which is the only directional signal available, and it rests on other drug classes rather than on peptide bioregulators.
Pre-existing conditions: Malignancy history, immunosuppression, bleeding disorders and active infection each amplify the specific hazards above: proliferative signalling, impurity-driven immune activation, injection-site bleeding and inoculation of contaminated material.
Age: Older adults carry more undiagnosed malignancy, thinner skin and more anticoagulant use, so injections bruise more and form haematomas (pockets of blood under the skin). Reduced kidney and liver function also slows clearance of impurities.

Key Interactions & Contraindications

All interactions below are inferred from pharmacology and from the injectable route. No interaction study of Cardiogen exists.

Anticoagulants and antiplatelet agents, which reduce clotting (warfarin, apixaban, clopidogrel, low-dose aspirin): Caution. Subcutaneous injection into an anticoagulated person raises haematoma and injection-site bleeding risk. Mitigation: fine-gauge needle, firm compression, no intramuscular route.
Over-the-counter analgesics (ibuprofen, naproxen, aspirin): Caution. Their antiplatelet action adds to injection-site bruising and can mask the low-grade fever that signals an endotoxin reaction. Mitigation: no routine dosing around injection days.
Over-the-counter antihistamines (cetirizine, loratadine, diphenhydramine): Monitor. Routine pre-dosing blunts early hypersensitivity signs, delaying recognition of a reaction. Mitigation: use reserved for treating a reaction rather than preventing one.
Prescribed cardiovascular therapy (beta blockers, which slow the heart, such as metoprolol; angiotensin-converting enzyme inhibitors, which relax vessels, such as lisinopril): Monitor. No interaction is known; the risk is crediting a peptide with changes driven by dose adjustment. Mitigation: no dose changes during a course.
Other peptide bioregulators (Epitalon, Pinealon, Vesugen, Cartalax): Caution. Stacking is common, multiplies unverified exposure and sterility burden, and makes attribution impossible. No additive data exist. Mitigation: single-agent courses only.
Supplements with additive cardiac effects (coenzyme Q10, taurine, L-Carnitine, D-Ribose): Caution. These target the same claimed domain of cardiac energetics and cell maintenance, so concurrent use confounds every monitored marker. Mitigation: stable intake across the observation window.
Supplements with additive bleeding effects (fish oil, nattokinase, garlic extract, high-dose vitamin E, Ginkgo biloba): Caution. Additive platelet inhibition worsens injection-site bruising and haematoma, particularly alongside prescribed anticoagulation. Mitigation: high-dose use separated from injection days.
Concurrent interventions (new resistance or endurance training blocks, sauna protocols, cardiac rehabilitation): Monitor. These move blood pressure, resting heart rate and inflammatory markers on their own. Mitigation: steady training volume while any peptide course is running.

Populations who should avoid Cardiogen:

Active malignancy, or any cancer treated within the past 5 years, given proliferative signalling and reduced p53
Pregnancy and lactation, with no reproductive or developmental toxicity data of any kind
Age under 18
Active infection or febrile illness, which both raises inoculation risk and confounds inflammatory markers
Bleeding disorders such as haemophilia, platelet count below 50 × 10⁹/L, or anticoagulation with an international normalised ratio above 3.5
Decompensated heart failure, New York Heart Association Class III-IV, or myocardial infarction (heart attack) within 90 days
Severe liver impairment, Child-Pugh Class C, or advanced kidney disease with an estimated glomerular filtration rate below 30 mL/min/1.73 m²
Known hypersensitivity to any peptide preparation, or to benzyl alcohol, the preservative in bacteriostatic water

Risk Mitigation Strategies

Pharmacy-sourced material only: Using a licensed compounding pharmacy rather than a research-chemical vendor addresses the documented endotoxin and mislabelled-purity hazards, since only the former operates under sterility and content specifications.
Lot-specific certificate review: Requiring a certificate of analysis for the exact lot, covering purity, mass confirmation, sterility and endotoxin, mitigates dose and identity error. Suppliers frequently run contaminant panels on a rotating subset of lots only.
Malignancy screening before any course: Age-appropriate cancer screening completed within 12 months addresses the tumour-promotion concern arising from reduced p53 and increased proliferation, which no study has excluded.
Single-agent courses: Running Cardiogen alone rather than stacked with other bioregulators mitigates compounded unknown exposure and makes any adverse event attributable to one compound rather than four.
Aseptic injection technique: Alcohol preparation, single-use needles, site rotation across abdomen, thigh and upper arm, and discarding any cloudy solution mitigate injection-site infection, abscess and inoculation of degraded material.
Cold-chain and expiry discipline: Storing lyophilised (freeze-dried) vials at 2-8 °C and discarding reconstituted solution after 30 days mitigates degradation products, which are the same species implicated in impurity-driven immune reactions.
First-dose observation: Administering an initial reduced dose and observing for 60 minutes for fever, shaking chills, flushing or urticaria (hives) mitigates the endotoxin and hypersensitivity reactions that carry the only documented human evidence in this section.

Therapeutic Protocol

No clinical protocol exists. Nothing below has been validated in a human study, and the doses circulating bear no derived relationship to the concentrations used in the underlying experiments.

Standard circulating protocol: Community and vendor sources converge on 10 mg subcutaneously every 3 to 7 days, run as a 2 to 4 week cycle. No trial supports this dose, frequency or duration.
Intensive variant: A 20 mg subcutaneous dose on the same 3 to 7 day interval circulates as the higher-exposure option, sometimes extended weekly to 16 weeks. The step from 10 to 20 mg is arbitrary rather than dose-ranging.
Competing oral approach: The Russian tradition uses oral capsule courses of 10 to 30 days, repeated two or three times yearly, arguing that gut peptide transporters carry the intact sequence. Bioavailability is unmeasured either way.
Origin of the approaches: Both routes trace to Vladimir Khavinson’s Saint Petersburg Institute of Bioregulation and Gerontology, which developed the compound. No independent clinic or research group has published a competing protocol.
Time of day: Morning administration is the convention, on the reasoning that it aligns with the daytime peak of cardiac workload. No study of dosing time for this peptide exists to support or refute it.
Half-life and its consequence: Tetrapeptides of this class are cleaved by plasma and tissue peptidases within minutes, so intermittent large doses produce brief spikes rather than sustained exposure. No measured half-life for Cardiogen has been published.
Single versus split dosing: Circulating protocols use a single dose per administration day. Given minutes-long clearance, splitting would not extend exposure meaningfully, and no comparison of the two schedules exists.
Genetic considerations: Variants in SLC15A1 and SLC7A5, the transporter genes proposed to carry the peptide into cells, would alter delivered exposure. No pharmacogenetic dosing guidance exists, and testing has no validated interpretation here.
Sex-based considerations: No protocol distinguishes by sex, and no dosing, response or efficacy comparison between men and women has been reported for Cardiogen or for any peptide in this family.
Age considerations: Circulating protocols do not adjust for age, although the preclinical rationale rests entirely on aged tissue. Adults past 70 carry more anticoagulant use and thinner skin, which affects injection practice rather than dose.
Baseline biomarkers: Protocols specify no entry biomarkers. Recording inflammation, natriuretic peptide and troponin before a course is the only way to interpret any later change, since no expected response range exists.
Pre-existing conditions: Nothing in circulation adjusts for cardiac, liver or kidney status. Where those systems are impaired, the practical concern is clearance of impurities and diluent rather than of the peptide.

Discontinuation & Cycling

Not designed as lifelong use: Every circulating protocol is finite. Courses run 2 to 4 weeks, with the extended variant reaching 16 weeks, and none proposes continuous administration on the model of a chronic cardiovascular medicine.
Cycling convention: A 3 to 6 month break between courses is the standard interval, justified by the general bioregulator claim that intermittent signalling is sufficient. No study compares cycled with continuous dosing for any outcome.
No withdrawal effects reported: No withdrawal syndrome has been described for Cardiogen or for the peptide bioregulator family. This reflects the absence of human observation rather than demonstrated safety on stopping.
Tapering not applicable: No receptor occupancy, feedback suppression or dependence mechanism is proposed, and courses are already intermittent, so no tapering schedule exists or is theoretically indicated.
Practical stopping rule: Fever, shaking chills, spreading redness at the injection site, hives or breathlessness after a dose are grounds for immediate discontinuation, since these match the endotoxin and hypersensitivity hazards documented for this supply channel.

Sourcing and Quality

Two distinct supply routes: Freeze-dried research-chemical vials, typically 20 mg at roughly USD 44-60, and oral capsule preparations from the originating Russian programme. Neither route is an approved medicine in any jurisdiction.
What a certificate should show: Chromatographic purity at or above 98%, mass spectrometry confirming 489.5 daltons, sequence confirmation as Ala-Glu-Asp-Arg, plus separate sterility and endotoxin reports carrying the same lot number as the vial.
The rotating-panel problem: Suppliers commonly state that endotoxin, sterility and heavy-metal testing run on a rotating subset of lots rather than on every lot, so a purity certificate on the vial in hand may carry no contaminant data at all.
Label content is not delivered content: Published lot certificates for nominally 20 mg vials have reported measured peptide content varying by a quarter or more from the label, so a stated milligram dose describes the vial, not the administered amount.
Compounding pharmacies versus chemical suppliers: Research-chemical vendors state explicitly that they are not 503A or 503B compounding pharmacies. Only a licensed compounder operates under sterility, content and beyond-use-date requirements, and most will not compound this peptide.
Third-party testing: Independent laboratory verification is the single most useful signal, but the industry norm is supplier-commissioned testing on selected lots. Requesting the raw chromatogram and the endotoxin report for the specific lot is the practical check.
Storage and handling: Lyophilised material holds at 2-8 °C protected from light and should not be frozen; reconstitution uses bacteriostatic water, and any cloudy, yellow or particulate solution indicates degradation.

Practical Considerations

Time to effect: Unknown, because no human outcome has ever been measured. Circulating expectations of cellular change by weeks 2 to 4 are extrapolated from cell-culture timescales of 24 to 72 hours, not from anything observed in people.
Common pitfall, treating research-use labelling as a formality: The label reflects the absence of sterility, content and stability requirements. That gap is where the documented endotoxin contamination and purity shortfalls actually arise.
Common pitfall, stacking: Running Cardiogen alongside three or four other bioregulators is routine in community protocols and makes any observed change, good or bad, unattributable to a single compound.
Common pitfall, mistaken identity: Searches for Cardiogen return CardioGen-82, an approved rubidium-82 generator used for cardiac imaging. The two share nothing but a name, and safety information for one does not apply to the other.
Regulatory status: Not approved as a medicine anywhere, not a lawful dietary supplement in the United States, and sold only as a research chemical. Related longevity peptides sit in the restricted compounding category maintained by the U.S. Food and Drug Administration.
Cost and access: Inexpensive by longevity-intervention standards at roughly USD 50 per 20 mg vial, entirely out of pocket, and easy to obtain online without prescription. Low cost and easy access are precisely what remove pharmacy oversight from the transaction.
Payer incentives shape the evidence: Guideline cardiovascular prevention runs on generics costing cents daily, already funded by insurers and national systems. An unapproved peptide is self-paid, so no institutional payer has reason to sponsor a trial — a structural bias in what gets studied.

Interaction with Foundational Habits

Sleep: No direct interaction is proposed or observed; Cardiogen has no known central nervous system activity and clears within minutes. The indirect route runs through adverse events: a low-grade endotoxin reaction after an evening dose disturbs sleep through fever and malaise, which is one argument for the morning administration convention.
Nutrition: Direct and mechanistically relevant. The peptide is proposed to enter cells through the same transporters that carry dietary amino acids and di- and tripeptides, so a protein-containing meal supplies competing substrate. Where an oral route is used, protocols separate dosing from meals by 30 to 60 minutes.
Exercise: No potentiating or blunting effect is known, and no study has combined the two. The practical interaction is confounding: a new training block moves resting heart rate, blood pressure and inflammatory markers by more than any plausible peptide effect, so holding training volume steady is what makes monitoring interpretable.
Stress management: Indirect only. No effect on cortisol or the stress response has been examined for Cardiogen. Chronic stress raises the same inflammatory markers the peptide is proposed to lower, so unmanaged stress both worsens the target state and obscures whether anything changed.

Monitoring Protocol & Defining Success

Because no expected response has ever been established in people, monitoring here serves two purposes: detecting harm, and giving any observed change a baseline to be compared against. Before a first course, a reasonable panel covers inflammation, cardiac wall stress and myocardial injury, lipid particle burden, and organ safety, alongside seated blood pressure, resting heart rate and a resting electrocardiogram (a recording of the heart’s electrical activity). Age-appropriate cancer screening completed within the past year belongs in the same baseline, given the proliferative signalling involved. Repeat testing at 4 weeks, at the end of a course, and then every 6 to 12 months captures both the acute safety window and any slower drift, with an unscheduled panel after any febrile or injection-site reaction.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
High-sensitivity C-reactive protein	Below 0.5 mg/L	Tracks the cell-ageing inflammation the peptide targets, and rises with contamination reactions	Abbreviated hs-CRP. Conventional labs call below 3.0 mg/L average risk; invalid within 2 weeks of infection or injury
Interleukin-6	Below 1.5 pg/mL	Second inflammatory signal, less affected by acute infection than hs-CRP	Conventional reporting often below 7 pg/mL; draw fasting and at a consistent morning hour
N-terminal pro-B-type natriuretic peptide	Below 50 pg/mL under age 65	Reflects heart wall stretch, the closest routine proxy for the claimed cardiac benefit	Abbreviated NT-proBNP. Conventional cutoff is 125 pg/mL; rises with age, atrial fibrillation and reduced kidney function
High-sensitivity cardiac troponin T	Below 5 ng/L	Detects ongoing myocardial injury and any new insult during a course	Conventional 99th percentile is about 14 ng/L; avoid drawing within 24 hours of hard exercise
Apolipoprotein B	Below 80 mg/dL	Carries the actual artery-narrowing burden that no peptide claim addresses	Conventional targets run 90-130 mg/dL; non-fasting draw is acceptable
Estimated glomerular filtration rate	Above 90 mL/min/1.73 m²	Clearance capacity for injected impurities and diluent	Abbreviated eGFR, a measure of kidney filtering. Conventional threshold for concern is 60; creatinine is raised by recent creatine supplementation
Alanine aminotransferase	Below 25 U/L in men, below 20 U/L in women	Organ safety screen for any unapproved injected compound	Abbreviated ALT, a liver enzyme. Conventional upper limits reach 40-55 U/L; pair with gamma-glutamyl transferase
Absolute eosinophil count	Below 200 cells/µL	Early signal of hypersensitivity to synthesis by-products	Conventional threshold is 500 cells/µL; part of a complete blood count with differential
Seated blood pressure	110-120 / 70-75 mmHg	Cheapest cardiovascular endpoint available and a check on unexpected circulatory change	Conventional normal reaches 120/80 mmHg and treatment thresholds start at 130/80; average three morning readings across a week
Resting heart rate	50-65 bpm	Sensitive to inflammatory and febrile reactions before symptoms appear	Conventional normal runs 60-100 bpm; measure on waking, before rising, and trend matters more than any single value

Qualitative markers worth recording alongside the panel:

Exercise tolerance at a fixed workload, such as heart rate at a set pace or wattage
Breathlessness on exertion and any change in usual exercise capacity
Palpitations, chest discomfort or new exercise intolerance, each of which warrants stopping
Injection-site appearance over 48 hours: redness, hardening, bruising, warmth
Fever, shaking chills or flu-like malaise within 12 hours of a dose
Sleep quality and daytime energy, tracked simply enough to be recorded daily

Emerging Research

No registered trial of the compound: A ClinicalTrials.gov search on 1 September 2026 for Cardiogen, its sequence and the Khavinson bioregulators returned no interventional study. The only registry record matching the name belongs to a rubidium-82 imaging generator with no relationship to the peptide.
Peptide signalling tested against cardiovascular ageing: NCT05301192 infuses angiotensin-(1-7), a short endogenous peptide, in 26 healthy adults aged 65-80, measuring sympathetic nerve activity and blood vessel function. It is the human endpoint class Cardiogen’s file lacks entirely. Early Phase 1, recruiting.
Peptides against cell-ageing endpoints: NCT07456449 randomises 125 adults aged 50-70 to collagen peptides or placebo for 24 weeks, with telomere length and telomerase activity (the enzyme that rebuilds the protective caps on chromosome ends) as primary outcomes. It illustrates the design and scale a peptide longevity claim requires.
Whether the peptide enters cells at all: Transport through amino acid and peptide carriers rests on docking simulations (Khavinson et al., 2023). Direct uptake assays in heart muscle cells would either anchor the mechanism or remove its foundation, and none has been published.
Independent characterisation of the family: A Polish pharmacy group’s appraisal of the sibling tetrapeptide Epitalon (Araj et al., 2025) found the structural and physicochemical literature sparse after 25 years of biological claims. Comparable scrutiny of Cardiogen would test the class rather than extend it.
Regulatory trajectory: The restricted compounding category covers several longevity peptides, and a 2026 advisory committee narrowly recommended six for compounding. The pharmacies and clinics that petitioned for that change bill for these preparations; the regulator does not.
Where the funding gap sits: A four-amino-acid sequence published decades ago cannot carry composition-of-matter protection, so no manufacturer and no insurer has a financial reason to fund an outcome trial. The evidence gap is structural, not merely a matter of time.

Conclusion

Cardiogen is a four-amino-acid compound designed to act on heart tissue and sold as a laboratory chemical rather than as a medicine. Its supporting record is small and one-sided: living heart tissue kept in dishes grows more and shows less of the protein that pushes damaged cells to die, cultured connective-tissue cells make more structural protein, and aged rats carrying a transplanted tumour show slowed tumour growth. Almost all of it comes from the institute that created the compound and holds the commercial interest in it, and none of it involves people, which is why every claimed benefit sits at the lowest confidence this review’s grading allows.

The concerns run the other way. Blunting the cell’s self-destruct signal and stirring connective-tissue cells are the same actions that could favour unwanted growth or scarring. And because the compound reaches buyers through an unlicensed channel, the most concrete documented harms belong to the channel rather than to the molecule: vials carrying fever-inducing bacterial residue, and a fraction of the purity printed on the label.

Regulators have placed related compounds in a restricted category, while the clinics and suppliers arguing to loosen that restriction earn their income from the outcome. Both positions carry an interest. No human finding of any kind exists, favourable or otherwise, and the reasons for that absence are commercial as much as scientific.

Top - Benefits - Risks - Protocol

Cardiogen for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Speculative 🟨

Proliferative Activity in Aged Heart Tissue

Suppression of Apoptotic Signalling in Heart Tissue

Structural Protein Output in Fibroblasts

Tissue-Selective Action Across Organs

Damping of Cell-Ageing Inflammatory Signalling

Tumour Growth Restraint in Aged Rats

Post-Infarction Survival Benefit (Patent-Only Claim)

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Immune Reactions to Synthesis By-Products

Endotoxin Exposure from Unregulated Vials

Dose and Identity Error from Mislabelled Product

Injection-Site Infection and Local Reactions

Speculative 🟨

Weakening of a Tumour-Suppressor Pathway

Action on Tumour Blood Supply

Pro-Fibrotic Drift in Cardiac Fibroblasts

Off-Target Binding to Histones and DNA

Uncharacterised Reproductive and Genotoxic Effects

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion